Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical Holdings Group announced the successful renewal and inclusion of its innovative drug, Anjiuwei, in the 2025 National Reimbursement Drug List (NRDL) in China. This renewal is expected to stabilize market sales and enhance the drug’s penetration, supporting its long-term growth. Anjiuwei, developed by Xuanzhu Biopharm, a Sihuan subsidiary, is a proton pump inhibitor approved for treating duodenal ulcers. Its innovative design makes it a safer option for patients with multiple medications or renal insufficiency, filling a gap in China’s domestic market for such treatments.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group, founded in 2001 and listed on the Hong Kong Stock Exchange in 2010, is an international company focused on medical aesthetics and pharmaceuticals. It boasts a robust R&D platform, a diverse product pipeline, and efficient production capabilities. The company aims to be a leader in China’s medical aesthetics and biopharmaceutical sectors, driven by innovation and a strong sales system.
YTD Price Performance: 103.05%
Average Trading Volume: 44,226,805
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.41B
For an in-depth examination of 0460 stock, go to TipRanks’ Overview page.